Show simple item record

dc.contributor.authorPeeters, M
dc.contributor.authorPrice, T
dc.contributor.authorCervantes, A
dc.contributor.authorSobrero, A
dc.contributor.authorDucreux, M
dc.contributor.authorHotko, Y
dc.contributor.authorAndré, T
dc.contributor.authorChan, E
dc.contributor.authorLordick, F
dc.contributor.authorPunt, C
dc.contributor.authorStrickland, A
dc.contributor.authorWilson, G
dc.contributor.authorCiuleanu, T
dc.contributor.authorRoman, L
dc.contributor.authorVan Cutsem, E
dc.contributor.authorTzekova, V
dc.contributor.authorCollins,
dc.contributor.authorOliner, K
dc.contributor.authorRong, A
dc.contributor.authorGansert, J
dc.date.accessioned2011-01-20T17:29:59Z
dc.date.available2011-01-20T17:29:59Z
dc.date.issued2010-11-01
dc.identifier.citationRandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 2010, 28 (31):4706-13 J Clin Oncolen
dc.identifier.issn1527-7755
dc.identifier.pmid20921462
dc.identifier.doi10.1200/JCO.2009.27.6055
dc.identifier.urihttp://hdl.handle.net/10541/120100
dc.description.abstractPanitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status.
dc.language.isoenen
dc.subjectAnticancerous Combined Chemotherapy Protocolsen
dc.subjectColorectal Canceren
dc.subjectCancer Stagingen
dc.subjectBiological Tumour Markersen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCamptothecin
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshColorectal Neoplasms
dc.subject.meshDisease-Free Survival
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshHumans
dc.subject.meshInfusions, Intravenous
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshLeucovorin
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMutation
dc.subject.meshNeoplasm Staging
dc.subject.meshPredictive Value of Tests
dc.subject.meshProspective Studies
dc.subject.meshProto-Oncogene Proteins
dc.subject.meshReceptor, Epidermal Growth Factor
dc.subject.meshTreatment Outcome
dc.subject.meshTumor Markers, Biological
dc.subject.meshras Proteins
dc.titleRandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentUniversity Hospital Ghent, Ghent, Belgium. Marc.Peeters@uza.been
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPanitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status.


This item appears in the following Collection(s)

Show simple item record